News
A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic and Wegovy, were linked to a 33% ...
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...
When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...
Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...
A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program ...
GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...
6h
Futurism on MSNA Side Effect of Trump's Tariffs: Making Ozempic Way More ExpensivePresident Donald Trump's new European tariffs may spell bad news for Novo Nordisk, maker of Ozempic and Wegovy. As Axios ...
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...
Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.
Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results